Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$16.48 USD
+1.56 (10.46%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $16.49 +0.01 (0.06%) 7:22 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/6/24 |
---|---|
Current Quarter | -0.67 |
EPS Last Quarter | -0.64 |
Last EPS Surprise | -12.28% |
ABR | 1.60 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -2.67 |
Next Year | -2.12 |
EPS (TTM) | -2.38 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | 0.88M | 13.60M | 87.66M |
# of Estimates | NA | 4 | 6 | 6 |
High Estimate | NA | 1.25M | 21.33M | 138.86M |
Low Estimate | NA | 0.56M | 3.40M | 15.10M |
Year ago Sales | 0.00M | 0.00M | NA | 13.60M |
Year over Year Growth Est. | NA | NA | NA | 544.75% |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.67 | -0.70 | -2.67 | -2.12 |
# of Estimates | 7 | 6 | 8 | 8 |
Most Recent Consensus | -0.66 | -0.67 | -2.79 | -1.92 |
High Estimate | -0.65 | -0.65 | -2.43 | -1.39 |
Low Estimate | -0.71 | -0.78 | -2.89 | -2.78 |
Year ago EPS | -0.59 | -0.61 | -2.37 | -2.67 |
Year over Year Growth Est. | -13.56% | -14.75% | -12.66% | 20.46% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 1 | 1 | 2 |
Up Last 30 Days | 0 | 1 | 1 | 2 |
Up Last 60 Days | 0 | 0 | 0 | 1 |
Down Last 7 Days | 0 | 1 | 1 | 1 |
Down Last 30 Days | 0 | 1 | 1 | 1 |
Down Last 60 Days | 5 | 5 | 7 | 5 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.67 | -0.70 | -2.67 | -2.12 |
7 Days Ago | -0.67 | -0.70 | -2.66 | -2.12 |
30 Days Ago | -0.67 | -0.70 | -2.66 | -2.12 |
60 Days Ago | -0.59 | -0.60 | -2.35 | -1.67 |
90 Days Ago | -0.57 | -0.58 | -2.31 | -1.63 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.67 | -0.73 | -2.68 | -1.74 |
Zacks Consensus Estimate | -0.67 | -0.70 | -2.67 | -2.12 |
Earnings ESP | 0.00% | -3.82% | -0.51% | 17.93% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.64 | -0.54 | -0.61 | -0.59 | NA |
Estimate | -0.57 | -0.60 | -0.60 | -0.60 | NA |
Difference | -0.07 | 0.06 | -0.01 | 0.01 | 0.00 |
Surprise | -12.28% | 10.00% | -1.67% | 1.67% | -0.57% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more